Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
AICAR (acadesine; 5-aminoimidazole-4-carboxamide ribonucleotide) — AMPK activator
A grey-market AMPK activator marketed as an 'exercise mimetic' on the strength of a single famous mouse study — Narkar 2008, where 4 weeks of AICAR boosted treadmill running endurance 44% in sedentary mice. That endurance signal has NEVER been shown in humans. The only human trials of AICAR (as the drug acadesine) were for a completely different purpose — protecting the heart during cardiac-bypass surgery — and the large, definitive RED-CABG randomized trial was NEGATIVE. AICAR has poor oral bioavailability (it's injected in studies), is WADA-banned as a doping agent, and is not an approved drug or a regulated supplement. There is no human exercise-performance evidence.
Research compound — not a dietary supplement
AICAR (Acadesine) is a research compound, not a regulated dietary supplement. It is sold for research or off-label use. The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
AICAR (Acadesine) doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1994–2026.
Based on 19 studies · 1 meta-analysis · 6 RCTs
Study base
19 studies indexedBy outcome
Every outcome below: Too few graded studies.
AICAR's 'exercise mimetic' reputation rests on a single mouse study (Narkar 2008, +44% running endurance in sedentary mice) — there is no human exercise or performance evidence at all. Its only large human trial, RED-CABG, tested a different indication (cardiac-surgery protection) and was negative. Add poor oral bioavailability and a WADA ban, and the off-label endurance/longevity use is barely-supported.
AICAR (5-aminoimidazole-4-carboxamide ribonucleotide; the drug name is acadesine) is a cell-permeable AMP analogue that activates AMP-activated protein kinase (AMPK), the cell's central energy sensor.
Because endurance exercise also activates AMPK and its downstream coactivator PGC-1α, AICAR has been promoted as an 'exercise mimetic' — a pill that supposedly delivers training adaptations without training.
That entire reputation rests on one landmark animal paper: Narkar et al., Cell 2008, which reported that 4 weeks of AICAR alone induced oxidative metabolic genes and increased treadmill running endurance by 44% in sedentary mice.
It is a genuinely important mechanistic result — but it is a mouse result, and the honest, load-bearing caveat is that nothing like it has ever been demonstrated in a human. There is no human endurance trial, no human performance trial, no human geroprotection trial of AICAR.
The only human clinical evidence comes from a completely separate indication: AICAR, infused intravenously as 'acadesine,' was tested in the 1990s and 2010s to protect the heart from ischemia/reperfusion injury during coronary-artery-bypass-graft (CABG) surgery.
A 1997 individual-patient meta-analysis of five trials (McSPI/Mangano, JAMA) suggested acadesine reduced early cardiac death, myocardial infarction, and combined adverse cardiac events — a positive human signal.
But the definitive, properly powered test, the RED-CABG randomized double-blind trial (Newman et al., JAMA 2012, ~3,000 patients across 300 sites), was NEGATIVE: acadesine did not reduce the composite of all-cause mortality, nonfatal stroke, or severe left-ventricular dysfunction, and the trial was stopped early for futility.
So even in the one indication where AICAR reached large human trials, the best evidence failed to support it — and that indication is cardiac surgery, not exercise or longevity.
Pharmacologically, AICAR has poor oral bioavailability; the meaningful studies dose it by injection or infusion, which is why grey-market oral or even injectable 'AICAR' has no validated human regimen.
It is banned by the World Anti-Doping Agency (WADA) as a metabolic modulator, it is not approved by any regulator as a medicine, and it is not a lawful dietary-supplement ingredient — material sold online is an unregulated research chemical with no identity, purity, or sterility guarantee.
The score is LOW: a striking preclinical mechanism and an interesting (but ultimately negative) human cardiac-surgery story, with zero human exercise-performance evidence, poor bioavailability, and a doping ban.
AICAR is taken into cells and converted to ZMP, an AMP analogue that allosterically activates AMP-activated protein kinase (AMPK) — the master energy sensor that exercise also switches on. This is the proximal mechanism behind every claimed effect.
Downstream of AMPK, PGC-1α coordinates mitochondrial biogenesis and a shift toward oxidative, fatigue-resistant muscle fibres. In sedentary mice this drove the increase in running endurance — demonstrated in rodents, never in humans.
AMPK activation by AICAR promotes GLUT4-mediated glucose uptake (via Tbc1d1) and increases fatty-acid oxidation in muscle — the metabolic basis for the 'exercise-like' phenotype. Shown in cell and animal models only.
How AICAR (Acadesine) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Avoid absolutely — AICAR is WADA-prohibited and will trigger an anti-doping violation.
Avoid — there is no human exercise/longevity evidence; the endurance data are entirely from mice and the human (cardiac) trial was negative.
Avoid entirely — unstudied for this use.
AICAR and metformin both activate the AMPK pathway; combining AMPK activators has not been studied for safety in this context and could compound metabolic effects unpredictably.
AMPK activation promotes glucose uptake; theoretical additive hypoglycemia risk with insulin or insulin secretagogues. No human interaction data for off-label use.
Acadesine infusion caused transient increases in serum uric acid in cardiac-surgery trials; relevance to other settings is unknown.
The available source did not grade how severe these reactions were. This does not mean they were mild.
Tip: Seen with IV acadesine in cardiac-surgery trials; monitor in anyone with gout/urate issues. Other effects of grey-market use are uncharacterized.
Tip: No human has been studied taking AICAR for endurance or longevity — the side-effect profile in that setting is genuinely unknown.
Tip: Grey-market material (especially injectables) has no identity/purity/sterility guarantees; contamination and dosing errors are possible.
AICAR (Acadesine) has an evidence score of 3.1/10 — emerging evidence based on 19 indexed studies, including 1 meta-analysis. A grey-market AMPK activator marketed as an 'exercise mimetic' on the strength of a single famous mouse study — Narkar 2008, where 4 weeks of AICAR boosted treadmill running endurance 44% in sedentary mice. That endurance signal has NEVER been shown in humans. The only human trials of AICAR (as the drug acadesine) were for a completely different purpose — protecting the heart during cardiac-bypass surgery — and the large, definitive RED-CABG randomized trial was NEGATIVE. AICAR has poor oral bioavailability (it's injected in studies), is WADA-banned as a doping agent, and is not an approved drug or a regulated supplement. There is no human exercise-performance evidence. Representative study: PMID 9002496.
Dosing for AICAR (Acadesine): No self-directed dose is recommended by SupStack. AICAR is an unapproved, WADA-banned research chemical with no validated human regimen. We do NOT provide a dosing protocol. The only human dosing on record is intravenous infusion of acadesine during cardiac surgery (0.1 mg/kg/min for ~7 hours), which is a hospital ischemia protocol, not an exercise or longevity dose, and which failed its definitive trial.
Timing is flexible for AICAR (Acadesine) — consistent daily use matters more than the time of day. There is no validated human exercise/longevity dosing schedule.
No consumer dose of AICAR (Acadesine) is endorsed, so there is no dose at which it can be called safe. Talk to a healthcare provider before taking it. Reported side effects include unknown human side-effect profile for exercise/longevity use, harm from an unregulated, impure or non-sterile product, transient hyperuricemia (raised serum uric acid). How often they occur is not established for all of them. Use caution if any of these apply to you: Not an approved medicine and not a regulated dietary supplement — unapproved grey-market research chemical; do not self-source; Banned by WADA in and out of competition — disqualifying for any tested athlete; No human exercise/longevity safety data exists — every such conclusion would be an extrapolation from animals.
Caffeine
HelpedBlocks adenosine receptors to boost alertness, reaction time, and endurance — an umbrella review of 21 meta-analyses found it ergogenic for endurance, strength and power.
CoQ10
HelpedA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
Sodium Bicarbonate
No clear benefitErgogenic aid that buffers metabolic acid. An umbrella review of meta-analyses found it improves peak anaerobic power and efforts lasting about 45 seconds to 8 minutes, on moderate to low quality evidence.
Alpha-GPC
Too few graded studiesA choline source that crosses the blood-brain barrier. Trials show cognitive gains in people with dementia or after stroke. In healthy adults the data are a few small, short studies.
Explore: Best supplements for Athletic Performance
Edited by Dr. Baher Al Hakim · Last updated November 2026 · evidence from 19 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
AICAR (Acadesine)
AMP-analogue AMPK activator marketed as an 'exercise mimetic' — grey-market, WADA-banned, poorly oral-bioavailable
AMPK activation
Converted to ZMP, an AMP mimic that activates AMP-activated protein kinase — the same energy sensor exercise switches on
PGC-1α / mitochondrial biogenesis
AMPK drives PGC-1α, mitochondrial biogenesis, and a shift to oxidative, fatigue-resistant fibres (preclinical)
GLUT4 uptake / fatty-acid oxidation
AMPK promotes GLUT4-mediated glucose uptake (via Tbc1d1) and fatty-acid oxidation in muscle (cell/animal)
Endurance & metabolism (mice only)
In sedentary mice, 4 weeks of AICAR raised running endurance 44% and improved metabolism — never demonstrated in humans
Bioavailability & translation gap
Poor oral bioavailability (injected in studies); the only large human trial (RED-CABG, cardiac surgery) was negative; WADA-banned